×

Orig3n™ Acquires Interleukin Genetics, a Genetics-Based Personalized Health Company, to Advance the Future of Health Faster

BOSTON, Nov. 22, 2017 /PRNewswire/ -- Orig3n, Inc., a Boston-based biotech company pioneering the future of health through genetics and regenerative medicine research, today announced the acquisition of Interleukin Genetics CLIA laboratory and their remaining assets. Interleukin Genetics' technology will become a core component of Orig3n's DNA test business to empower more people to take charge of their health through genetic insights.

Interleukin Genetics brings exceptional and valuable assets to Orig3n, including a CLIA-Certified Genetics Laboratory in Waltham, Massachusetts. The automated genotyping lab is fully-licensed for testing in all 50 U.S. states and is capable of processing over one million samples per year. In addition to the company's state-of-the-art technology and its HIPAA and HITECH compliance, Interleukin Genetics also brings its ILUSTRA™ Inflammation Management Program and its Inherent Health® genetic tests for nutritional needs, weight management, heart health, and bone health to Orig3n. All personalized genetic tests will be consolidated under the Orig3n brand.

"Once we met with Interleukin Genetics, we saw a natural alignment between the two organizations regarding our shared commitment to a future of personalized health," said Robin Y. Smith, CEO of Orig3n. "With our trajectory of accelerated growth, we couldn't imagine a better fit for acquisition. We are very pleased to be welcoming Interleukin Genetics to Orig3n."

Orig3n's regenerative medicine research lab will remain in Boston's Innovation District and the genetic testing will be consolidated to Interleukin Genetics' CLIA laboratory. Rene Oda, previously the Director of Technology at Interleukin Genetics will join Orig3n as the Director of Product Management and Dr. Lynn Doucette-Stamm, joins as Senior Vice President of Development and Clinical Operations.

"We are looking forward to using our skillsets with Orig3n's to expand the array of direct-to-consumer DNA tests," said Dr. Lynn Doucette-Stamm. "We see innovative growth opportunities ahead and we're very excited to be joining a company focused on furthering the common good and advancing the future of health through genetics and regenerative medicine research."

About ORIG3N, Inc.
Founded in 2014, ORIG3N exists at the intersection of biological science and emerging technology. Through our DNA tests and community events, we help people understand the links between their genes and how their minds and bodies work. Our research team uses cutting-edge cellular science to develop personalized therapies for repairing tissue damage and disease. Together with our community, we're on a mission to accelerate the future of health. For more information, visit www.orig3n.com.

Orig3n's Guiding Beliefs:

  • We believe people should have direct, affordable access to information about their genes and their health.
  • We believe that when people better understand the links between genes, health, and behavior, they can make educated, proactive choices about their future.
  • We believe people should be in control of how their genetic information is used.
  • We believe diagnosing and treating disease shouldn't be a matter of trial and error.

About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics. Interleukin Genetics' lead products include our proprietary cardiovascular test to guide treatment of high risk patients; our proprietary ILUSTRA Inflammation Management Program; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit www.ilgenetics.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/orig3n-acquires-interleukin-genetics-a-genetics-based-personalized-health-company-to-advance-the-future-of-health-faster-300561135.html

SOURCE Orig3n, Inc.